Disruption of p53 in human cancer cells alters the responses to therapeutic agents.

We have examined the effects of commonly used chemotherapeutic agents on human colon cancer cell lines in which the p53 pathway has been specifically disrupted by targeted homologous recombination. We found that p53 had profound effects on drug responses, and these effects varied dramatically depending on the drug. The p53-deficient cells were sensitized to the effects of DNA-damaging agents as a result of the failure to induce expression of the cyclin-dependent kinase inhibitor p21. In contrast, p53 disruption rendered cells strikingly resistant to the effects of the antimetabolite 5-fluorouracil (5-FU), the mainstay of adjuvant therapy for colorectal cancer. The effects on 5-FU sensitivity were observed both in vitro and in vivo, were independent of p21, and appeared to be the result of perturbations in RNA, rather than DNA, metabolism. These results have significant implications for future efforts to maximize therapeutic efficacy in patients with defined genetic alterations.

[1]  K. Kinzler,et al.  A model for p53-induced apoptosis , 1997, Nature.

[2]  A. Kinsella,et al.  p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. , 1996, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[3]  Wyllie Ah.  Apoptosis and carcinogenesis. , 1997 .

[4]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[5]  Bert Vogelstein,et al.  Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21 , 1996, Nature.

[6]  Y Li,et al.  [Mitochondria and apoptosis]. , 2000, Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine].

[7]  G. L. Carter,et al.  Effect of 5-fluorouracil on RNA metabolism in Novikoff hepatoma cells. , 1979, Cancer research.

[8]  Y. Cheng,et al.  Metabolism and mechanism of action of 5-fluorouracil. , 1990, Pharmacology & therapeutics.

[9]  K. Kinzler,et al.  p21 is necessary for the p53-mediated G1 arrest in human cancer cells. , 1995, Cancer research.

[10]  Michael Weller,et al.  Predicting response to cancer chemotherapy: the role of p53 , 1998, Cell and Tissue Research.

[11]  Stephen J. Elledge,et al.  Mice Lacking p21 CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control , 1995, Cell.

[12]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[13]  James Brugarolas,et al.  Radiation-induced cell cycle arrest compromised by p21 deficiency , 1995, Nature.

[14]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[15]  John M. Sedivy,et al.  Gene Targeting in Human Cells Without Isogenic DNA , 1999, Science.

[16]  J. Grem,et al.  Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells. , 1994, Oncology research.

[17]  V. Ferrans,et al.  Reactive oxygen species are downstream mediators of p53-dependent apoptosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Grem,et al.  Enhanced cytotoxicity with interleukin-1α and 5-fluorouracil in HCT116 colon cancer cells , 1994 .

[19]  K. Kinzler,et al.  14-3-3σ Is a p53-Regulated Inhibitor of G2/M Progression , 1997 .

[20]  Bert Vogelstein,et al.  Cell-cycle arrest versus cell death in cancer therapy , 1997, Nature Medicine.

[21]  J. Benhattar,et al.  p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas , 1996, International journal of cancer.

[22]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[23]  G. Demers,et al.  Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. , 1996, Cancer research.

[24]  J. McDougall,et al.  Telomerase activation by the E6 gene product of human papillomavirus type 16 , 1996, Nature.

[25]  S. Lyons,et al.  Apoptosis and carcinogenesis. , 1999, British medical bulletin.

[26]  S. Friend,et al.  Which guesstimate is the best guesstimate? Predicting chemotherapeutic outcomes , 1997, Nature Medicine.

[27]  C. Potten,et al.  Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Fisher.  Apoptosis in cancer therapy: Crossing the threshold , 1994, Cell.

[29]  D. Lane,et al.  p53 In tumour pathology: Can we trust immunohistochemistry?—revisited! , 1994, The Journal of pathology.

[30]  K. Kinzler,et al.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.

[31]  S. Lowe,et al.  Cancer therapy and p53. , 1995, Current opinion in oncology.

[32]  P. Petit,et al.  Commitment to apoptosis is associated with changes in mitochondrial biogenesis and activity in cell lines conditionally immortalized with simian virus 40. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Levine,et al.  Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy , 1999, Oncogene.